Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Bullboard Posts
Post by SABBOBCATon Dec 20, 2019 10:29am
133 Views
Post# 30476505

Credibility

Credibility
I haven’t seen the report and would love to know what the Analyst’s rational was for the PT cut. However, I have had some thoughts at this time of year when TH has tended to trade at its lowest levels, and those thoughts echo others’ concerns with management. Last year my posts were very frustrated by the apathetic attitude and silence from the company, but this year is a different story. The company does appear to be making more of an effort and is getting better at actively engaging investors. Unfortunately, when you get a report with a garbage PT it makes you wonder what is going on. I was first frustrated again with the lack of a proper IR team, but TH is making strides on that front. So, then my thoughts turned to the Analysts perceptions of the management team, and their ability to execute on their proposed plan. That is where I believe TH still struggles. Management has a huge credibility issue in my eyes, and it is not one that is easily fixed. They can either earn the credibility back through improved performance and execution, or they can “buy” credibility by hiring a new CEO with the resume and the connections to get the wheels turning. The first option is a long struggle and where we are at now. The latter could be a quicker fix but would be a costly endeavor to attract the right talent. 

The company can and will keep trying to attract investors with the “new” story, but the market has heard such things before and is going to play the wait and see game. The question going through each investors’ head is “Why should I put my money behind these yahoos? I have seen them a dozen times or so over the last 10 years and each time they talk a big game before flopping out on the field”. 
 
So while I agree Luc is a brilliant mind, it may be time to get a salesman at the helm instead of the same old yahoos.  
 
Bullboard Posts